Figure 2.

iPSCs in EV production. iPSCs can be differentiated into various cell types that have therapeutic potential. iPSC-NK cells have the advantages of increased expansion potential, the production of biologically young cells, and less donor variation compared to primary NK cells. For EV production, several iPSC-derived cells and iPSCs themselves have been shown to produce functional EVs. However, for NK cells, studies investigating iPSC-NKEVs have not been reported, raising the important question of whether iPSC-NK cells produce EVs. NKEVs can reproduce the functions of NK cell therapies while reducing the complexity and immunogenicity of the final therapeutic product, thus increasing safety. These features highlight how iPSC-NKEVs represent an important direction for NKEV research.